Perspectives and opportunities for nanomedicine in the management of atherosclerosis

Mark E. Lobatto; Valentin Fuster; Zahi A. Fayad; Willem J.M. Mulder

doi:10.1038/nrd3578

Perspectives and opportunities for nanomedicine in the management of atherosclerosis

Mark E. Lobatto, Valentin Fuster, Zahi A. Fayad, Willem J.M. Mulder

Research output: Contribution to journal › Review article › peer-review

349 Scopus citations

Abstract

The use of nanotechnology for medical purposes ĝ€" nanomedicine ĝ€" has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.

Original language	English
Pages (from-to)	835-852
Number of pages	18
Journal	Nature Reviews Drug Discovery
Volume	10
Issue number	11
DOIs	https://doi.org/10.1038/nrd3578
State	Published - Nov 2011

Access to Document

10.1038/nrd3578

Cite this

@article{4ae45f6a2a0c440ca135f9fd9722fff6,

title = "Perspectives and opportunities for nanomedicine in the management of atherosclerosis",

abstract = "The use of nanotechnology for medical purposes ĝ€{"} nanomedicine ĝ€{"} has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.",

author = "Lobatto, {Mark E.} and Valentin Fuster and Fayad, {Zahi A.} and Mulder, {Willem J.M.}",

note = "Funding Information: We gratefully acknowledge D. P. Cormode for discussions and recommendations. Support for this work was partially provided by the International Atherosclerosis Society (M.E.L). This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) and the US National Institutes of Health (NIH), as a Program of Excellence in Nanotechnology (PEN) Award (Contract no. HHSN268201000045C), as well as by the NIH grants R01 EB009638 (Z.A.F.) and R01 CA155432 (W.J.M.M.).",

year = "2011",

month = nov,

doi = "10.1038/nrd3578",

language = "English",

volume = "10",

pages = "835--852",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Perspectives and opportunities for nanomedicine in the management of atherosclerosis

AU - Lobatto, Mark E.

AU - Fuster, Valentin

AU - Fayad, Zahi A.

AU - Mulder, Willem J.M.

N1 - Funding Information: We gratefully acknowledge D. P. Cormode for discussions and recommendations. Support for this work was partially provided by the International Atherosclerosis Society (M.E.L). This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) and the US National Institutes of Health (NIH), as a Program of Excellence in Nanotechnology (PEN) Award (Contract no. HHSN268201000045C), as well as by the NIH grants R01 EB009638 (Z.A.F.) and R01 CA155432 (W.J.M.M.).

PY - 2011/11

Y1 - 2011/11

N2 - The use of nanotechnology for medical purposes ĝ€" nanomedicine ĝ€" has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.

AB - The use of nanotechnology for medical purposes ĝ€" nanomedicine ĝ€" has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.

UR - http://www.scopus.com/inward/record.url?scp=80255129385&partnerID=8YFLogxK

U2 - 10.1038/nrd3578

DO - 10.1038/nrd3578

M3 - Review article

C2 - 22015921

AN - SCOPUS:80255129385

SN - 1474-1776

VL - 10

SP - 835

EP - 852

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 11

ER -

Perspectives and opportunities for nanomedicine in the management of atherosclerosis

Abstract

Access to Document

Fingerprint

Cite this